CGEM
Cullinan Therapeutics, Inc.
A clinical-stage biopharmaceutical company in Cambridge, Massachusetts that develops experimental therapies for cancer and autoimmune diseases, advancing drug candidates it discovers or licenses through early clinical trials. Founded in 2016 as Cullinan Pharmaceuticals, it rebranded to Cullinan Therapeutics in 2024 to signal its shift beyond oncology into autoimmune conditions. Its name nods to the Cullinan Diamond, the largest gem-quality rough diamond ever found, evoking rarity and brilliance.
CUSIP: 230031106HealthcareUS1 holder
Total Value
$5.51M
Total Shares
429.6K
Net Share Change
-1.11M
Activity
1 selling
Investor
Value
Shares
Weight
Change
